Arkema S.A. (AKE) Earnings Call Transcript
July 30, 2026
Earnings Call Speaker Segments
Good morning. I'm the conference operator. Welcome, and thanks for being with us on the Arkema second quarter 2026 results and outlook conference call. Please note that everyone is in listen-only mode. Following the presentation, you'll have a chance to ask questions by pressing star and 1 at any time. If anyone requires assistance during the conference call, they can signal an operator by pressing star and 0 on their telephone. At this point, I'd like to hand the conference over to Mr. Thierry Le Hénaff, Chairman and Chief Executive Officer. Please go ahead, sir.
Thanks a lot. Morning, everyone. Glad to have you on Arkema's Q2 2026 results conference call. With me today are Marie-José Donsion, our CFO, and the Investor Relations team. For this call, we've posted a set of slides that you can find on our website. I'll start by covering the quarter's highlights, then hand it over to Marie-José to walk through the financials. At the end of the presentation, as usual, we'll take your questions. The second quarter was marked by the challenging situation in the Middle East. Oil and raw material prices, along with energy and logistics costs, went up sharply because of the conflict, and global supply chains were disrupted in part. There was some temporary relief toward the end of the quarter, but after the cease-fire, fighting broke out again, and raw material prices climbed once more. Overall market demand stayed weak, consistent with the prior quarter, with no recovery yet in Europe and the US. Asia, on the other hand, remained well oriented, especially Southeast Asia and India, while China's domestic growth was more muted. Against this complex backdrop, Arkema put in a good second-quarter performance, with EBITDA up 7% year-on-year to €391 million, despite a €10 million currency headwind.
The EBITDA margin came in at a pretty robust level of 16.1%, which is a 90 basis point gain versus a year ago. That represents a meaningful step up, and it's the first time in several quarters that EBITDA has moved higher year-on-year. The main drivers behind this gain were the strong results in our Adhesives and Coating businesses, whereas High Performance Polymers held roughly flat. The letdown, as we had anticipated and previously signaled, was Performance Additives. More fundamentally, what these results show is the quality of Arkema's portfolio, and they mirror the strategic transformation we've carried out over the years to concentrate the group on higher value-added applications and appealing growth markets. I'd like to take a moment now to highlight the hard work and dedication of our teams, who are still fully mobilized to soften supply chain disruptions—both when it comes to raw materials availability and input cost inflation—working closely alongside our suppliers and our customers. Turning briefly to how our Specialty Materials segments performed: Adhesive Solutions delivered a strong quarter, with EBITDA rising 7% year-on-year. Incidentally, this was Bostik's best quarter ever, matching Q2 2022. That result was chiefly fueled by the segment's ongoing product mix shift toward higher value-added solutions, along with pricing actions aimed at passing through raw material inflation.
So volumes came in largely flat overall. We saw solid gains in durable goods segments — notably aerospace, consumer electronics, and industrial assembly. That was partly counterbalanced by construction volumes that landed slightly under what we expected, especially in Europe, and by packaging, which stayed weak. Against demand that is still sluggish, our EBITDA margin rose to a healthy 15.1%, which speaks to the team's continued work on making this segment more profitable. Advanced Materials posted uneven results this quarter, as you saw. High Performance Polymers picked up some steam, helped by new business development, project ramp-ups, and nice growth in batteries, 3D printing, and electronics. PIAM had yet another very strong quarter, with EBITDA climbing 30% in local currency. Fluorospecialties fell short of forecasts, though they ought to pick up during the second half of the year. Taking it all together, HPP's EBITDA matched last year's figure. Performance Additives, by contrast, dropped considerably, hit by the Middle East crisis, with demand especially weak in certain end markets like refining and fertilizers, plus a sizable rise in sulfur costs. Overall, the Advanced Materials segment's margin held at a healthy level of roughly 19%, which still leaves room to do better.
Coating Solutions posted a robust rebound during the quarter. EBITDA rose sharply compared with the low base set in 2025. Both our resin and our additive operations turned in solid results, though I want to call out in particular the favorable momentum at Sartomer, which achieved strong volume gains across the quarter, especially in electronics, 3D printing, and industrial coatings. The segment's results also mirror the continuing shift of the portfolio toward higher value-added applications, along with nimble pricing management. Consequently, we felt very good about the segment margin, which climbed to a high level of 18.5%. Turning to Intermediates, as we had expected, earnings were shaped by tighter spreads in acrylics, partly offset by the phasing out of old generation refrigerant. In Asia, acrylic spreads fell quickly, returning to where they had been before, whereas in Europe and the US, spreads have recovered more gradually, and that only contributed modestly to earnings growth, since the volume picture has stayed subdued up to now. During Q2 we likewise kept concentrating on rigorous cost discipline and cash allocation. At the close of June, we are on track with our goal of offsetting fixed cost inflation across the full year, which would represent quite an achievement, backed by a range of cost-cutting initiatives throughout the organization.
We keep a tight grip on working capital as well, and our CapEx sit under last year's level, right on track with the annual target we set. Because of that, the group managed to produce a solid amount of recurring cash flow during the quarter — close to €80 million — and that was not a given given rising raw material costs. Continuing to roll out our long-term strategy also matters. From that angle, ramping up our major projects stayed among our priorities, and that includes, recently, our polyamide 11 and Rilsan Clear plant in Singapore and our new PVDF capacity in the US, which has recently started up. We additionally kicked off the new distillation in acrylics at our Carling site in France, which lets the group cut that site's carbon footprint by 20% and its energy consumption by 25%. Taken together, our growth projects added roughly €25 million of extra EBITDA in H1 compared with last year, fully in line with our target for the full year. I'll now pass things to Marie-José for a deeper dive into the financials before we turn to the outlook at the close of the presentation.
Thanks, Thierry, and good morning to all of you. I'll begin with Arkema's revenues, which stood at €2.4 billion. Organically, Q2 sales rose 3.2% compared with a year earlier. Volumes were a touch lower, at 1.8%, reflecting generally soft demand across Europe and North America as well as reduced volumes in Performance Additives. On pricing, the effect was a positive 5.1%, mirroring both the pricing measures the group rolled out in every business to offset raw material inflation and improved market conditions in upstream acrylics. Scope had a minor negative impact, at -0.7%, tied to the divestment of certain small plastic additives businesses on the 1st of July. Finally, a currency effect that remained negative, at 1.2%, weighed on sales, mirroring the US dollar's weakening against the euro. That impact was milder than during the first quarter. EBITDA for quarter two reached €391 million, a rise of 7% year-on-year, chiefly fueled by robust results in Adhesive Solutions and Coating Solutions, whereas Advanced Materials declined versus a year earlier, hurt by the softer showing of Performance Additives, while the High Performance Polymers held steady. Intermediates drew substantial support from better spreads in acrylics. The quarter two EBITDA figure absorbed an unfavorable currency impact of €10 million.
Depreciation and amortization came in at €171 million, which brought recurring EBIT to €220 million — an 11% increase — while the REBIT margin rose to 9%. Nonrecurring items totaled €78 million. Those comprised €32 million of PPA depreciation along with €46 million of one-off charges, tied notably to the reorganization at our Jarrie and Pierre-Bénite sites in France that began last year, to legal proceedings still underway, and to the divestment of certain small plastic additives businesses that closed recently. Financial expenses were -€35 million, mainly mirroring the higher cost of our refinanced bonds. Adjusted net income for quarter two reached €129 million, equal to €1.70 per share. Turning to cash flow and net debt: Arkema posted strong cash flow generation in quarter two. Recurring cash flow was €78 million, which reflects working capital that stayed well controlled. The working capital ratio on annualized sales came to 15.8%, a marked improvement over last year's 17%. I want to take this chance to commend the teams, who managed working capital strictly even as raw material costs climbed. All in all, the free cash flow the group delivered in the first half was a solid print, a touch better than last year.
In quarter two, total capital expenditure came to €170 million, which matches our guidance for annual CapEx of under €600 million across the full year '26. At the close of June, net debt and hybrid bonds stood at €3.6 billion, and that figure includes €800 million of hybrid bonds. Year-on-year, our debt held steady, which confirms how solid our balance sheet is in a weak market condition. At present, the ratio of net debt to last 12 months EBITDA is roughly 2.9 times. Thank you for your attention, and we'll now hand it back over to Thierry.
Thanks, Marie-José. As you can see, even with the tough backdrop, we managed a solid result in Q2, with EBITDA up versus the prior year. If we look at the first half, performance came in where we wanted it, though Q1 was somewhat disappointing and Q2 landed a bit above expectations. At constant FX, EBITDA for H1 was marginally higher than a year earlier, bearing in mind that the first half was the stronger half of last year and that conditions grew tougher during the second half for every chemical company. Going into Q3, demand patterns are largely the same. The conflict still underway in the Middle East keeps limiting how much visibility we have on raw material cost trends and continues to weigh on the macro picture. Against that backdrop, our teams stay agile and disciplined, keeping a constant emphasis on operational excellence and pricing management so we can steer through the current conditions. Cash generation and capital allocation remain key priorities for Arkema, underpinned by rigorous working capital management and a disciplined approach to CapEx. At the same time, we keep building Arkema for the future, and that includes carrying out the major projects you're familiar with.
As I mentioned earlier, we can confirm that these major projects will add roughly €50 million to the group's EBITDA compared with last year. Given what we achieved in H1 and the conditions we're currently seeing, we are reaffirming our guidance for 2026: a slight increase in EBITDA at constant exchange rates. The split between the two semesters would then come back to a traditional level. In H2, our results should get a notable boost from year-on-year growth in Adhesive Solutions and Coating Solutions. Many thanks for listening. Marie-José and I are now ready to take your questions.
Thanks. This is the conference operator speaking. The question-and-answer session is starting now. If you'd like to ask something, you can press star and 1 on your touch-tone phone. Should you want to be taken out of the question queue, just press star and 2. When you ask a question, please lift the receiver. At this point, anyone with a question can press star and 1. Our first question comes from Katie Richards at Barclays. Go ahead, please.
Morning, and thanks. I’ve got two questions, if I may. First, you mentioned stronger dynamics in the High Performance Polymers division compared with Q1. Could you expand on what’s behind that improvement, and do you have confidence that the business is back to growth for the rest of the year, excluding ramp-ups from new projects? Second, I’d be interested in your comments on regional dynamics. You noted some improvement in North America—could you say more about why you’re seeing those gains there?
Alright, thanks a lot for that question. When it comes to HPP, the drivers come from various sources. Obviously, the project's ramp-up plays a part, but we're seeing solid growth now in polyamide. There was, let's say, a substantial portion of the semester where things remained subdued, and then during the second quarter we began to notice the payoff from new business development, especially on High Performance Polymer for battery. Even auto performed somewhat better than anticipated, and I'd add electronics — again, battery — and semiconductors. All of these operations feed into that growth pocket we referenced. The bulk of that growth pocket sits essentially inside this HPP, and we ought to see those dynamics making a solid contribution in the second semester. Within HPP, perhaps among the various business lines, the one that's presently the most stable is specialty fluorospecialties. As a matter of fact, the growth is genuinely coming from the pure polymers — PIAM, PVDF, and polyamide. On NA, I'm not sure whether that was just about HPP or about the group as a whole. I'll assume it's about the group overall. I'd say, as I noted at the start of this call, regarding regional dynamics, we still see NA So there are a few exceptions.
Take aeronautics, for instance — everyone is aware it’s performing fairly well, yet for Arkema it isn’t a large market. Broadly speaking, NA remains a letdown when you look at underlying dynamics. Some of our business segments, I believe, are doing quite strongly, but on the whole we’re still in line with prior quarters, with subdued demand. Same story in Europe, as we said. From my perspective, on volume — after that, we could argue about the pricing narrative — but on volume, I’d say growth for Arkema really still originates in Asia, in China, though China is driven more by our customers’ exports out of China than by domestic demand itself, which truly isn’t so great. Then there’s Southeast Asia and India. Normally we don’t discuss it much, but the momentum in Q2 pleased us. Essentially the geographic balance stays more or less unchanged from earlier quarters. Maybe just to wrap up on NA — and you saw it in the coatings results release — the coatings dynamics in the US, Sartomer included, but even beyond that, are better than in prior quarters.
Thanks a lot. Appreciate it.
Glad to help.
The following question comes from Matthew Yates at Bank of America. You have the floor.
Morning, everyone. Thierry, I want to follow up on the final point you raised regarding Sartomer and perhaps take a few minutes to go deeper on that business, which historically may have flown a bit under the radar. If I recall correctly, it serves a wide range of end markets. Is the growth you're seeing a result of the capacity investments made in recent years now ramping up? Specifically, am I correct that UV resins are used for printed circuit boards, and does this connect to the strong growth we're seeing in semiconductors and so on? Last, because of the financial restatements you've made on the coatings business, tracking performance across the years is rather difficult, but would you agree that Sartomer is a very — and I stress the word very — a very margin-accretive franchise, and that this has been really important in explaining the 18% margin you delivered in the division this quarter? Thank you.
Thanks. Yes, Matthew. Yes, those questions are entirely fair. Yes, it is accurate that Sartomer actually did decline and over the last two years it was disappointing, especially last year, during a tougher stretch. At the same time we were taken aback, since this is a business we acquired quite a while ago, and we have real conviction about those products, which genuinely are accretive and high value. We began from a weak base last year, which was disappointing, and in this year we are seeing a robust rebound for several reasons. First, the Asian portion, helped by electronics, by semiconductor, and also medical applications, while 3D is performing rather well. Owing to the Middle East, and also supply chain disruption, the US portion, which was more, I would say, was more challenging, and surprisingly so given that we lead there, is returning to a much more respectable profitability level. In Europe we have very strong teams, and they have managed to keep things stable even in a difficult market. Sartomer overall was a bright spot, as you astutely noted, but it was not the sole one. The rheology additives via Coatex and the coatings, more conventional coating resins, are performing well.
Regarding that 18.5% figure for the second quarter, we're quite happy with it. Whether or not it becomes the new standard, it's probably wiser to look at the H1 average, given a somewhat soft first quarter combined with a really robust second quarter. What this tells us is that Coatings contains the elements needed to deliver a rather solid level of results once certain conditions line up. I believe that's a positive signal for you and for the market, since perhaps you raised a few questions previously that were fair, given that we observed some weaknesses nobody anticipated. As a matter of fact, we find that the moment conditions become slightly more favorable, we observe powerful leverage on this business's profitability, and that makes us quite happy. By separating acrylics — which sat upstream and carried more volatility, now reported back under Intermediates — from the coating solution itself, which is more the downstream piece, we gain improved understanding and transparency around profitability. On this second quarter, that clearly paid off.
Much appreciated.
Up next, we have a question from Chetan Udeshi at JPMorgan. Please go ahead.
Hello, and thank you for taking my question. Q2 was quite strong, but the makeup of the EBITDA growth caught me a little off guard, since it appears much of it — really all of it — comes from pricing, given that your volumes are lower. Looking even at Adhesives, volumes are flat while EBITDA has risen. It looks like there may be some phasing benefit from cheaper raw materials combined with higher prices. I'm not certain, but I think the heart of what I'm asking is this: how should we gain confidence that this earnings lift driven by pricing won't fade once the Middle East conflict-related tightness, or perhaps panic buying and so on, begins to unwind later this year? My second question: in your presentation, you mentioned that the start of Q3 is following the same trend as what you've seen in recent months. With that in mind, how are you viewing the third quarter — whether against Q2 or against last year? Thank you very much.
Alright, no — those questions are fair, but I believe the answers are pretty straightforward. If you look at it, the Middle East effect is part of the picture, though in Adhesives specifically, the Middle East has zero effect on that business. If anything, I'd argue that the further downstream you move, the more the Middle East situation becomes a problem, since raw material costs rise sharply. Adhesives, by its very nature, is a highly fragmented business, and we achieved our strongest Q2 ever in Adhesives. That tells us that internally we've got very powerful momentum going. The teams are working incredibly hard to bring profitability back after last year, which was a disappointment. I think they're performing well — especially since you brought up pricing, but you left out something, and that's mix. For instance, our durable goods business, which is quite accretive within Adhesives, is expanding very robustly on the strength of new business development, and we've found a growth pocket there — again in electronics, in batteries, in automotive — and that's very encouraging. Adhesives, I'd say, forms part of the answer to your question, because Adhesives is not at all a question of net pricing — rather, they've managed to offset the raw material increase, but they're only at par in the sense that achieving a sort of neutral raw material cost impact was not easy, though not positive.
That's one part of the answer. Beyond that, when it comes to pricing for specialty materials generally, I'd note that we've had a modest net positive on price, and that has come from coatings, though the bulk of the favorable pricing is arising from acrylics, as we expected — even in Asia, by June it had already returned to the pattern of the first quarter. For Q2 as a whole, speaking for us, and we did reflect on this, the Middle East situation helped acrylics, helped coatings a little, yet hurt Performance Additives. The gains at HPP were more than outweighed by the difficulties the Middle East situation was causing in Performance Additives. In short, we believe a large share of Q2 profitability — the substantial majority — truly stems from where we are positioned, our mix, and the team's efforts in an environment containing both positives and negatives, as you can see, and it really varies by business. Turning to Q3, I'd say we don't provide quarterly guidance. That's something we never do. There is full-year guidance, and it is fairly precise.
Following that, you can determine the weighting you prefer for Q3 versus Q4. In fact, we state that no quarter looks precisely identical. We observed this during the first semester. The same will hold in the second semester. Seasonality will be present, yet we have provided guidance — reaffirmed that guidance — indicating that we anticipate a second half reflecting a return to traditional seasonality across the two semesters, with a certain level of EBITDA growth in the second semester, mainly driven again by Adhesives and Coatings, and within that, I would mention specifically High Performance, where High Performance product and Performance Additives somewhat offset each other. That is our current thinking.
Understood — thank you so much.
Thank you for joining us.
Jaideep Pandya from Onfield Research has the next question. Go right ahead.
Thank you. First, I'd like to ask about upstream acrylics, where you mentioned some softening in Europe. I just want to get a sense of what happened there in Q2 on the upstream acrylics side, both in terms of product spreads and where we sit now relative to mid-cycle versus low-cycle, and also what your structural view is for this product line over the next 12 to 18 months. Second, on the Performance Additives piece of Advanced Materials, I'd like to understand what's really happening there: how much of it was the Middle East crisis having an effect, and how much is down to other factors that might be holding back performance, and again, when could we expect a full recovery? And the final question is really about the M&A pipeline for Adhesives, given that one of your competitors recently completed a fairly large acquisition. What are you seeing in the Adhesives M&A pipeline these days? Thanks a lot.
Thank you for those questions. On upstream acrylics I’ll keep this brief, since as you can tell, much of this call really concerns how the product mix in Specialty Materials is evolving. Across the three regions, upstream acrylics show differing momentum. I’ll speak about Europe in more detail shortly, but in Asia — and I believe we already covered this when I was in London in March — things there are moving very, very fast, yet in both directions. There was a surge, and then it dropped off rather sharply. We are back to square one, at fairly low levels. In Europe and the US, the story is somewhat similar: we began from a low point. Those regions were at a low cycle. What we’re seeing now is that it’s getting — well, it isn’t fantastic. It’s simply more normal. We’re back near mid-cycle, which hopefully means it’s something we can rely on going forward. That was necessary, because we sat below the reinvestment point. No clear volume. Now, when we refer to the slowdown in Europe, sometimes you have to — it was important to restore the margin, and that was our priority.
Rather than pursuing volume, which was more the policy last year when margins were difficult in any case, this year our approach was more balanced, and that's why you could see temporarily — you just can't extrapolate from one quarter — but in the second quarter we decided to bring the margin back to close to normalized conditions in Europe. When it comes to Performance Additives, it's always hard to separate all the factors. What's clear is that the Middle East is a big — it's the elephant in the room. Why? Because Performance Additives is really the business line that supplies, by the nature of its product, Performance Additives supplies to polymers, for example, and it has been impacted by the Middle East because an important part of their business is in the Middle East. Okay? On top of that, more indirectly, but in the end it was direct, it's like this. One of their big raw materials is sulfur, which has gone to the sky, and that has been a very big impact for them. Then, as part of the fertilizers, agrichemicals are linked to sulfur production, to sulfur costs. In fact, they had the three elements at the same time, and it has been a big factor.
Then there are additional factors — simply because of the worldwide situation, demand isn't bright, and they're feeling that too. That's the reason we hold a portfolio of business lines, and it's also, I think, why Q2 came in strong: while Performance Additives is underperforming, the remaining lines sit either around where we expect or even above expectations. That's what's attractive about the portfolio. So when could this factor reverse? The big question is when the Middle East situation ceases, and nobody knows. It's hard to answer your question. Again, in this situation there are pros and cons. The Middle East brings some positive impact and some negative impact. We handle them quickly and with agility. Last question on M&A in Adhesives: we have a pipeline, as usual. Naturally, everyone has a pipeline in Adhesives, but it isn't the priority today. The priority is what we did in Q2 — to bring profitability to where we want it. Over the past three, four years we made several acquisitions and also invested in CapEx for Adhesives. We also reorganized the top management in Adhesives a year ago. For me, the priority today — and I told the team this — is that you deliver organically.
If something truly exceptional shows up on the market, we can look at it, and in any case it would be a small bolt-on deal, not a large one. We can live without it. Making an acquisition in Adhesives is not the priority of the day in the current context. Let's focus on continuing to improve profitability. We have a lot of possibilities in all the different business line of Adhesives.
Alright, thanks.
Much appreciated.
James Hooper from Bernstein has the next question. Go right ahead.
Good morning, everyone, and thanks for taking my questions. I've got two, please. First, on cost controls: they look like they're working better than in prior years. Did you make any changes within the organization to encourage that? And is there room to go further than simply an offset starting in 2027 over the medium term? Second, I'd like to follow up regarding the margin profile of a few of the new projects you have. Are there meaningful startup costs tied to these? Put another way, do you expect these projects to form part of the mix effect you've mentioned for 2027 and 2028 once they're fully ramped up? Thank you.
All right. Regarding cost control, have we made any changes within the organization? In terms of how Arkema operates, I think we place a great deal of emphasis on empowerment. Clearly, then, given what I'd call the state of the global economy and with demand being subdued, at least in Europe and the US, the teams grasp quite well the necessity of controlling costs and offsetting inflation. The way we operate — that's Arkema's discipline, Arkema's mindset, Arkema's culture. It's not as if we roll out some kind of big plan built around one element that would overwhelm every other element. It's a combination of elements: taking advantage of retirement, strengthening creativity, achieving productivity, doing it all in a smooth manner. I think it has been fairly successful up to now. We are also on track with our 3% headcount reduction, and we are likewise attentive to any new ways of working, digital, where we are beginning to ramp up on digital. We have some quite good projects, and we'll get more and more. We have plenty — I'd say it really is a sum of initiatives, but the organization, for the most part, remains the same, though the objective has been reinforced because of the — because we are agile, because we adapt to whatever the economy is doing.
We really did deliver far. As you can see, there's a summary on page four of what we're doing, which explains that we're truly aligned with our objective. Now, frankly speaking, for the mid-term — let's say the coming three years — if we can offset inflation in a world of higher inflation, I'd sign for that right now. I think offsetting inflation is a good target for a chemical company; I wouldn't commit to more than that, but I'm ready to commit to trying to offset inflation over the next few years, as we said, and that comes with the 3% headcount reduction we've already announced. On the new project, once it's fully ramped up — though on some projects, like Singapore, it can take five years. On others, like PVDF, small debottlenecking expansion, it can take two years. Once fully ramped up, it's accretive to the company's margin, but ramping up takes a few years. On startup cost, I'd say that's no longer the case. Maybe it was a couple of years ago, but not anymore, or it's — yes.
There are additional costs out there, though all of them, you could say, sit within EBITDA. The sole item we treated as a nonrecurring cost was the Singapore startup cost, which was extremely material, and that is what we classified as nonrecurring. In any case, startup costs for any new project form part of the company's fixed cost.
Since we know the surge of large-scale and major projects has passed, we're now operating in a more incremental way. That's no longer a subject of discussion, and our attention has shifted back to ramping up the business. Our ramp-up is slower than what we anticipated three years ago, yet we are ramping up, and we will be in line with our target for this year. Okay.
Appreciate it.
Our following question comes from Laurent Favre at BNP Paribas. You have the floor.
Yes. Morning. Apologies, but I'll return to the Adhesives remarks for the second half, since it appears you're quite confident that this will produce EBITDA growth for the group. That puzzles me somewhat, because the comparables are precisely identical across the first half and the second half when it comes to volumes. When I consider raw material inflation, it's possible not all of that inflation showed up in Q2. And on volumes, pre-buys seem more probable than postponed orders. I'm simply asking, with all this uncertainty and all the problems surrounding construction especially, what is driving that confidence? I'm not saying I question your confidence. I'm just asking what's behind it. No, but
I think, if I remember correctly, last year the first quarter was actually stronger than our first half, which in turn was stronger than the second half. We'll be growing against a base that was disappointing last year, and you know that I took some action following the results that, in my view for Adhesives, fell short of our expectations. I think last year's base wasn't a strong one, and I think we'll grow off that base. Now we're seeing, particularly in durable goods, after a lot of work, a lot of good momentum in new business development, and that will help. On the pre-buys, I don't really agree with you on Adhesives, because if you look at volume growth, we're at zero. We were at zero in Q2, and we're at zero for H1 — you don't see a difference between the first quarter and the second quarter. In the first quarter, obviously, there were no pre-buys. Between construction and the rest of the business, clearly, it will come from industrial adhesives more than from construction. No, I think we have good momentum. Now, we're not going to say that growth in Adhesives will be fantastic. We will be growing in Adhesives in the second half.
During the first half of the year, we've been expanding. Everyone's happy with that, and once more, it's against a prior-year comparison that wasn't great. All right.
I appreciate that.
No problem at all.
Just a reminder: to sign up for a question, hit star and 1 on your phone. If you have any more questions, press star and 1 again. Mr. Le Hénaff, nobody else is queued up right now. I'll hand things back to you for any closing comments.
All right, thanks to everyone for those questions — always interesting. If anything else comes up, please don't hesitate to reach out to Béatrice or James. They'll be really open. I hope you all get a summer break too, a very nice one. Looking forward to speaking with you again. Thank you.
Thanks, everyone, for being here. That brings the conference to a close. You're welcome to hang up your phones now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Arkema S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Arkema S.A. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.